halcinonide and amcinonide

Topics: Administration, Topical; Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Halcinonide; Humans; Male; Middle Aged; Ointments; Pregnenediones; Psoriasis; Random Allocation; Triamcinolone

Thirty-three patients with acute or subacute eczematous dermatitis were treated for two weeks in a double-blind, parallel-group study to compare the efficacy and cosmetic acceptability of 0.1 percent amcinonide cream and 0.1 percent halcinonide cream. Patients in both treatment groups showed significant (p less than 0.05) improvement from baseline for most signs and symptoms at the three evaluation times (days 3, 7, and 14). Comparisons between groups showed no significant differences at any evaluation except at day 14, when the amicinonide-treated patients had significantly (p = 0.04) less edema. The physician's evaluations were not significantly different except at day 7, when the halcinonide patients showed significantly (p = 0.04) more overall improvement. The patients' overall evaluations were not significantly different at any time. In general, both creams were cosmetically acceptable. At day 3, seven amcinonide patients noted skin tightening compared to one halcinonide patient; four halcinonide patients (as well as two at day 7 and one at day 14) reported stinging compared to only one amcinonide patient. In addition, two halcinonide patients reported a burning sensation at one or more evaluations compared to no such reports from amcinonide patients. One other side effect, a metallic taste in the mouth, occurred in a halcinonide-treated patient.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Female; Halcinonide; Humans; Male; Middle Aged; Ointments; Pregnenediones; Random Allocation; Triamcinolone

A 2-week, double-blind clinical trial was conducted to compare the efficacy and cosmetic acceptability of amcinonide cream 0.1 percent and halcinonide cream 0.1 percent in the treatment of 29 patients with eczematous dermatitis. The dermatologic status of each patient was rated by improvement in clinical signs and symptoms, by the investigator's overall evaluation, and by two patient evaluations. Both medications produced statistically significant and equivalent improvement by Week 2. However, amcinonide was significantly favored in the efficacy evaluation of relief from burning pain at Week 2 and in patient acceptability evaluations in regard to the absence of burning, stinging, and itching on application. The role of propylene glycol in the formulation of the halcinonide cream as a contributing cause of irritation is noted.

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Double-Blind Method; Eczema; Halcinonide; Humans; Male; Middle Aged; Pharmaceutical Vehicles; Pregnenediones; Propylene Glycols; Triamcinolone